Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Solara Active Pharma Sciences Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 380.62 | 352.31 | 425.24 | 211.94 | 299.43 | 363.49 | 346.95 | 300.31 | 273.01 | 319.15 | 313.54 | 349.00 | 387.29 |
| Expenses + | 331.85 | 333.19 | 387.61 | 373.63 | 289.67 | 321.57 | 285.64 | 242.63 | 227.64 | 262.13 | 278.81 | 311.66 | 329.63 |
| Operating Profit | 48.77 | 19.12 | 37.63 | -161.69 | 9.76 | 41.92 | 61.31 | 57.68 | 45.37 | 57.02 | 34.73 | 37.34 | 57.66 |
| OPM % | 12.81% | 5.43% | 8.85% | -76.29% | 3.26% | 11.53% | 17.67% | 19.21% | 16.62% | 17.87% | 11.08% | 10.70% | 14.89% |
| Other Income + | 4.68 | 2.04 | -4.04 | -62.32 | -120.48 | 0.56 | 0.32 | 1.49 | 5.95 | 0.98 | 0.49 | -6.75 | 5.55 |
| Interest | 21.96 | 24.61 | 24.44 | 25.37 | 30.69 | 30.87 | 28.28 | 26.54 | 29.12 | 23.90 | 20.83 | 22.45 | 27.57 |
| Depreciation | 26.45 | 25.91 | 26.21 | 25.96 | 25.25 | 25.07 | 25.34 | 24.54 | 24.30 | 23.58 | 24.49 | 25.57 | 26.04 |
| Profit before tax | 5.04 | -29.36 | -17.06 | -275.34 | -166.66 | -13.46 | 8.01 | 8.09 | -2.10 | 10.52 | -10.10 | -17.43 | 9.60 |
| Tax % | 25.40% | -34.91% | 0.00% | 0.00% | 53.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit + | 3.76 | -19.11 | -17.06 | -275.34 | -255.45 | -13.46 | 8.01 | 8.09 | -2.10 | 10.52 | -10.10 | -17.43 | 9.60 |
| EPS in Rs | 0.79 | -4.07 | -3.58 | -57.36 | -53.20 | -3.74 | 2.22 | 2.24 | -0.58 | 2.91 | -2.79 | -4.82 | 2.65 |
Financials of Solara Active Pharma Sciences Ltd
Annual income statement trend
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 |
| Expenses + | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,182 |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 187 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% | 14% |
| Other Income + | 2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | 0 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 95 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 100 |
| Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 | -7 |
| Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | 0% | 0% |
| Net Profit + | 0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | -7 |
| EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | 0.15 | -2.05 | |
| Dividend Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% | 0% | 0% |
Financials of Solara Active Pharma Sciences Ltd
Capital structure and asset base
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 | 45 |
| Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 | 1,208 |
| Borrowings + | 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | 687 |
| Other Liabilities + | 425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 | 393 |
| Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
| Fixed Assets + | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 | 1,238 |
| CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 | 205 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 5 |
| Other Assets + | 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 | 886 |
| Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
Financials of Solara Active Pharma Sciences Ltd
Operating, investing and financing cash movement
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 49 | 166 | 242 | 155 | -242 | 156 | 109 | 213 | 153 |
| Cash from Investing Activity + | -85 | -113 | -359 | -106 | -243 | -81 | -4 | -37 | -99 |
| Cash from Financing Activity + | 68 | -23 | 97 | 92 | 334 | -113 | -106 | -180 | -54 |
| Net Cash Flow | 31 | 30 | -20 | 142 | -151 | -38 | -0 | -4 | 1 |
| Free Cash Flow | 14 | 108 | -25 | -16 | -451 | 46 | 69 | 173 | 101 |
| CFO/OP | 92% | 85% | 103% | 49% | -277% | 106% | -113% | 104% | 83% |
Financials of Solara Active Pharma Sciences Ltd
Working capital efficiency and return ratios
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 | 93 | 117 |
| Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 | 170 |
| Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 | 145 | 146 |
| Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 | 133 | 140 |
| Working Capital Days | -124 | -22 | -32 | 16 | 37 | 20 | -128 | -62 | -23 |
| ROCE % | 10% | 12% | 15% | -0% | 2% | -9% | 6% | 5% |